Invention Description
Rapid identification of bacterial antibiotic susceptibility is critical for selecting effective treatments and combating antimicrobial resistance. However, conventional antimicrobial susceptibility testing (AST) methods rely on culture-based techniques that can take days to produce results, delaying appropriate therapy and increasing the risk of resistant infections. This challenge is especially significant for slow-growing multidrug-resistant bacteria. There is a need for faster, accurate methods to determine antimicrobial susceptibility and minimum inhibitory concentrations (MICs).
Researchers at Arizona State University have developed a rapid phenotypic AST system which integrates multichannel Large-Volume Scattering imaging (LVSim), capable of simultaneously monitoring multiple bacterial samples, with a Bayesian Gaussian process model that analyzes bacterial growth dynamics. Validated using standard clinical strains, this system enables the precise and rapid determination of minimum inhibitory concentrations (MICs) within two hours, dramatically reducing the time compared to traditional 16-20 hour AST methods. This system supports timely and effective treatment against multidrug-resistant bacterial infections such as those seen in sepsis.
This technology represents a rapid and accurate antimicrobial susceptibility testing method combining multichannel large-volume scattering imaging with Bayesian modeling to combat multidrug-resistant infections.
Potential Applications
- Clinical microbiology laboratories for rapid antibiotic susceptibility testing
- Hospitals managing sepsis, bloodstream infections, and multidrug-resistant bacterial outbreaks
- Development and validation of new antibiotics requiring fast phenotypic susceptibility profiling
- Point-of-care diagnostics in urgent care settings demanding rapid infection treatment guidance
- Research institutions studying bacterial growth dynamics and resistance mechanisms.
- Pharmaceutical companies accelerating drug discovery with rapid AST platforms
Benefits and Advantages
- Drastically reduced time-to-result, yielding MICs within 2 hours versus 16-20 hours
- High sensitivity capable of detecting slow-growing and multidrug-resistant bacterial isolates
- Advanced Bayesian modeling reduces data variability and refines growth curve and growth rate estimations
- Enables early susceptibility assessment, even for challenging pathogens such as Pseudomonas aeruginosa
- Simultaneous monitoring of up to eight sample/drug conditions for high-throughput analysis
- Single-cell resolution imaging via scattering techniques increases detection sensitivity
- Potential to improve patient outcomes through rapid, accurate antibiotic susceptibility results
For more information about this opportunity, please see